Melanoma of Non-Sun Exposed Skin in a Man with Previous Prostate Cancer: Recognition of a Recently Confirmed Association
Tóm tắt
The association of an increased risk to develop melanoma in patients with prostate cancer has recently been confirmed. The postulated etiologic relationship between prostate cancer and the subsequent occurrence of melanoma is discussed. A man with previous prostate cancer who developed melanoma on the plantar surface of his left great toe is described and the possibility of high levels of endogenous androgens promoting not only prostate cancer, but also increased risk of melanoma are reviewed. Modification of the host immune response, alteration of chromosome telomere length, and/or imbalance of androgen level (presenting as severe teenage acne) are potential mechanisms whereby high levels of endogenous androgens may contribute to the association between prostate cancer and risk of melanoma. An increased surveillance for melanoma should be considered in prostate cancer patients. Complete skin examination in men who have had prostate cancer—especially in those individuals diagnosed with prostate cancer prior to age 68 years—should regularly be performed.
Tài liệu tham khảo
Ingraffea A. Melanoma. Facial Plast Surg Clin North Am. 2013;21:33–42.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
Morvillo V, Luthy IA, Bravo AI, Capurro MI, Portela P, Calandra RS, Mordoh J. Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases. Melanoma Res. 2002;12:529–38.
Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84:1156–228.
Rumke P, Persijn JP, Korsten CB. Oestrogen and androgen receptors in melanoma. Br J Cancer. 1980;41:652–6.
Rampen FHJ, Mulder JH. Malignant melanoma: an androgen-dependent tumour? Lancet. 1980;1:562–5.
Bosland MC, Mahmoud AM. Hormones and prostate carcinogenesis: androgens and estrogens. J Carcinog. 2011;10:33.
Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann NY Acad Sci. 2006;1089:168–76.
Hyde Z, Flicker L, McCaul KA, Almeida OP, Hankey GJ, Chubb SAP, Yeap BB. Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol Biomarkers Prev. 2012;21:1319–29.
Bosland MC. The role of steroid hormones in prostate carcinogenesis (Chapter 2). J Natl Cancer Inst Monogr. 2000;27:39–66.
Gann PH, Hennekens CH, Ma J, Christopher L, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118–26.
Li W-Q, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, Han J. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol. 2013;31:4394–9.
Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol. 2011;147:1395–402.
Braisch U, Meyer M, Radespiel-Troger M. Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany. Eur J Cancer Prev. 2012;21:552–9.
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CG, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85:1571–9.
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35.
Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011;29:3677–85.
Hsueh EC, Gupta RK, Lefor A, Reyzin G, Ye W, Morton DL. Androgen blockade enhances response to melanoma vaccine. J Surg Res. 2003;110:393–8.
Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012;12:289–97.
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24–37.
Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy. 2013;5:169–82.
Cohen PR: Telomeres and telomerase: Can a topical telomerase activator reverse cutaneous aging? Cutis blog; 2013. http://www.cutis.com/the-publication/the-roundup-blog/article/telomeres-and-telomerase-can-a-topical-telomerase-activator-reverse-cutaneous-aging/8a3a0c17f111301a92fe5517a9e7a842.html. Last access Feb 11, 2014.
Lunau K. How long will you live? Maclean’s Mag. 2013;126(19, 20):65–8.
Nan H, Du M, DeVivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, Qureshi AA, Hunter DJ, Han J. Shorter telomeres associated with a reduced risk of melanoma development. Cancer Res. 2011;71:6758–63.
Calado RT, Yewdell WT, Wilkerson KL, Regal JA, Kajigaya S, Stratakis CA, Young NS. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114:2236–43.
Zhou J, Richardson M, Reddy V, Menon M, Barrack ER, Reddy GP-V, Kim S-H. Structural and functional association of androgen receptor with telomeres in prostate cancer cells. Aging. 2013;5:3–17.
Kim S-H, Richardson M, Chinnakannu K, Bai VU, Menon M, Barrack ER, Reddy GP-V. Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 2010;285:10472–6.
Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379:361–72.
Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer. 2007;121:2688–92.